Kazia Therapeutics (KZIA) Receivables - Other (2017 - 2025)
Kazia Therapeutics' (KZIA) quarterly Receivables - Other came in at $202128.1 in Q4 2025, up 249.47% YoY from $57839.2 in Q4 2024, and up 249.81% on a QoQ basis from $57782.4 in Q2 2025.
Kazia Therapeutics (KZIA) Receivables - Other (2017 - 2025) Analysis & Trends
Kazia Therapeutics (KZIA) has 8 years of Receivables - Other data on file, last reported at $202128.1 in Q4 2025.
- Quarterly Receivables - Other rose 249.47% year-over-year to $202128.1 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $202128.1 (up 249.47% YoY) and the FY2025 annual result came in at $57782.4, down 34.08% from the prior year.
- Receivables - Other rose to $202128.1 in Q4 2025, from $57782.4 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $460551.9 in Q4 2022 to a low of $26039.6 in Q4 2023.
- A 5-year average of $121113.1 and a median of $58181.7 in 2021 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2023 — Receivables - Other slumped 94.35% — and 2025, when it soared 249.47%.
- Tracing KZIA's Receivables - Other over 5 years: stood at $58524.2 in 2021, then jumped by 686.94% to $460551.9 in 2022, then tumbled by 94.35% to $26039.6 in 2023, then surged by 122.12% to $57839.2 in 2024, then soared by 249.47% to $202128.1 in 2025.
- The last three Receivables - Other figures came in at $202128.1 (Q4 2025), $57782.4 (Q2 2025), and $57839.2 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kazia Therapeutics | 4.22 Bn | 4.22 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 202,128.09 |
| Dec 31, 2025 | 202,128.09 |
| Jun 30, 2025 | 57,782.45 |
| Jun 30, 2025 | 57,782.45 |
| Dec 31, 2024 | 57,839.19 |
| Dec 31, 2024 | 57,839.19 |
| Dec 31, 2023 | 26,039.62 |
| Dec 31, 2023 | 26,039.62 |
| Jun 30, 2023 | 69,509.49 |
| Jun 30, 2023 | 69,509.49 |
| Dec 31, 2022 | 460,551.92 |
| Dec 31, 2022 | 460,551.92 |
| Jun 30, 2022 | 36,529.68 |
| Jun 30, 2022 | 36,529.68 |
| Jun 30, 2021 | 58,524.19 |
| Jun 30, 2021 | 58,524.19 |
| Jun 30, 2020 | 371,623.50 |
| Jun 30, 2020 | 371,623.50 |
| Jun 30, 2019 | 395,066.36 |
| Jun 30, 2019 | 395,066.36 |